Cocaine dependence

Last updated

Cocaine dependence
Specialty Psychiatry, clinical psychology

Cocaine dependence is a neurological disorder that is characterized by withdrawal symptoms upon cessation from cocaine use. [1] It also often coincides with cocaine addiction which is a biopsychosocial disorder characterized by persistent use of cocaine and/or crack despite substantial harm and adverse consequences. The Diagnostic and Statistical Manual of Mental Disorders (5th ed., abbreviated DSM-5), classifies problematic cocaine use as a stimulant use disorder. [2] The International Classification of Diseases (11th rev., abbreviated ICD-11), includes "Cocaine dependence" as a classification (diagnosis) under "Disorders due to use of cocaine". [3]

Contents

The use of cocaine creates euphoria and high amounts of energy. If taken in large doses, it is possible to cause mood swings, paranoia, insomnia, psychosis, high blood pressure, a fast heart rate, panic attacks, seizures that are extremely difficult to control, cognitive impairments and drastic changes in personality. Cocaine overdose may result in cardiovascular and brain damage, such as: status epilepticus, constricting blood vessels in the brain, causing strokes and constricting arteries in the heart; causing heart attacks. [4]

The symptoms of cocaine withdrawal range from moderate to severe: dysphoria, depression, anxiety, decreased libido, psychological and physical weakness, pain, and compulsive cravings.

Signs and symptoms

Cocaine is a powerful stimulant known to make users feel energetic, cheerful, talkative, etc. In time, negative side effects include increased body temperature, irregular or rapid heart rate, high blood pressure, increased risk of heart attacks, strokes and even sudden death from cardiac arrest. [5] [ self-published source ] Many people who habitually use cocaine develop a transient, manic-like condition similar to amphetamine psychosis and schizophrenia, whose symptoms include aggression, severe paranoia, restlessness, confusion [6] and tactile hallucinations; which can include the feeling of something crawling under the skin (formication), also known as "coke bugs", during binges. [7] Different ingestion techniques have their own symptoms that accompany them. Snorting it can cause a loss of sense of smell, nose bleeds, problems swallowing and an inflamed, runny nose. Smoking it causes lung damage and injecting it puts users at risk of contracting infectious diseases like HIV and hepatitis C. [8] Heavy users of cocaine have also reported having thoughts of suicide, unusual weight loss, trouble maintaining relationships, and an unhealthy, pale appearance. [6]

Withdrawal symptoms

When used habitually, cocaine can change brain structure and function, resulting in addiction. [8] Circuits within the brain structure that play a part in stress signals become more sensitive. When cocaine is not being used this increases an individual's displeasure and negative moods. [8] In 1986, Gawin and Kleber led an important study on the withdrawal symptoms of cocaine users. In this study, three distinct phases were reported. These phases are the 'crash', 'withdrawal' and 'extinction'. [9] The 'crash' phase or phase 1 occurs directly after cocaine is not being used anymore. Withdrawal symptoms for this phase are exhaustion, hypersomnia, no cravings to use, dysthymia, increased appetite, restlessness, and irritability. [9] The second phase, or 'withdrawal' phase occurs 1–10 weeks after cocaine users quit, symptoms include: lethargy, anxiety, erratic sleep, strong craving, emotional lability, irritability, depression, poor concentration, and bowel issues. [9] Finally the last phase or the 'extinction' phase occurs up to 28 weeks after discontinued use, symptoms include: episodic cravings and some dysphoria. [9]

Epidemiology and prevalence rates

Past Year Cocaine Use among People Aged 12 or Older: 2002-2019 (U.S.) Past-Year-Cocaine-Use-2002-2019.png
Past Year Cocaine Use among People Aged 12 or Older: 2002-2019 (U.S.)

In the United States, past year cocaine users in 2019 was 5.5 million for people aged 12 or older. When broken into age groups, ages 12–17 had 97,000 users; ages 18–25 had 1.8 million users and ages 26 or older had 3.6 million users. [10]

Past year cocaine users with a cocaine use disorder in 2019 was 1 million for people aged 12 or older. When broken into age groups, ages 12–17 had 5,000 people with a cocaine use disorder; ages 18–25 had 250,000 people with a cocaine use disorder and ages 26 or older had 756,000 people with a cocaine use disorder [10]

In the United States, cocaine use overdose deaths have been on the rise and in 2019, the CDC reported over 16,000 deaths from cocaine overdose. [11]

Risk

A study consisting of 1,081 U.S. residents who had first used cocaine within the previous 24 months was conducted. It was found that the risk of becoming dependent on cocaine within two years of first use was 5–6%. The risk of becoming dependent within 10 years of first use increased to 15–16%. These were the aggregate rates for all types of use considered, such as smoking, snorting, and injecting. Among recent-onset users individual rates of dependency were higher for smoking (3.4 times) and much higher for injecting. Women were 3.3 times more likely to become dependent, compared with men. Users who started at ages 12 or 13 were four times as likely to become dependent compared to those who started between ages 18 and 20. [12] [13] [14]

However, a study of non-deviant [nb 1] users in Amsterdam found a "relative absence of destructive and compulsive use patterns over a ten year period" and concluded that cocaine users can and do exercise control. "Our respondents applied two basic types of controls to themselves: 1) restricting use to certain situations and to emotional states in which cocaine's effects would be most positive, and 2) limiting mode of ingestion to snorting of modest amounts of cocaine, staying below 2.5 grams a week for some, and below 0.5 grams a week for most. Nevertheless, those whose use level exceeded 2.5 grams a week all returned to lower levels". [15]

Treatment

Therapy

Twelve-step programs such as Cocaine Anonymous (modeled on Alcoholics Anonymous) have been widely used to help those with cocaine addiction. Cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), rational emotive behavior therapy (REBT), and motivational interviewing (MI) can be especially powerful approaches to treating cocaine addiction. [16] Cognitive behavioral therapy combined with motivational therapy (MT) has proven to be more helpful than 12 step programs in treating cocaine dependency. [17] However, both these approaches have a fairly low success rate as research suggests that the withdrawal symptoms can last for several weeks. [18] [19] [20] For instance, one of the main predictors of a successful recovery is the number of continuous days a person is able to go without using the substance. [18] [21] Alternative holistic treatments such as physical exercise and meditation have been proven effective in reducing cocaine cravings. [4] Other non-pharmacological treatments such as acupuncture [22] [23] and hypnosis have been explored, but without conclusive results. [24] [25]

Medications

Numerous medications have been investigated for use in cocaine dependence, but as of 2015, none of them were considered to be effective. [26] Anticonvulsants, such as carbamazepine, gabapentin, lamotrigine, and topiramate, do not appear to be effective as treatment. [26] [27] Limited evidence suggests that antipsychotics are also ineffective for treatment of cocaine dependence. [28] Few studies have examined bupropion (a novel antidepressant) for cocaine dependence; however, trials performed thus far have not shown it to be an effective form of treatment for this purpose. [29]

The National Institute on Drug Abuse (NIDA) of the U.S. National Institutes of Health is researching modafinil, a narcolepsy drug and mild stimulant, as a potential cocaine treatment. Ibogaine [30] has been under investigation as a treatment for cocaine dependency and is used in clinics in Mexico, the Netherlands and Canada. It was legal for a time in Costa Rica, but has been illegal since 2018. It is illegal to use in many countries, such as Sweden, Norway, the United Kingdom, and in the United States. [31] Other medications that have been investigated for this purpose include acetylcysteine, baclofen, [32] and vanoxerine. [33] Medications such as phenelzine, have been used to cause an "aversion reaction" when administered with cocaine. [lower-alpha 1]

Vaccine

TA-CD is an active vaccine [35] developed by the Xenova Group which is used to negate the effects of cocaine, making it suitable for use in treatment of addiction. It is created by combining norcocaine with inactivated cholera toxin.

Research

Transcranial magnetic stimulation (TMS) is being studied as a treatment for cocaine addiction, although definitive evidence for efficacy does not yet exist. [36] [37]

Other research on rodents has suggested that cocaine use leads to complexes of dopamine transporters, which build up tolerance to the drug. [38] It's possible that future treatment for cocaine addiction might target those complexes. [38] Synaptogyrin-3, a synaptic vesicle protein, binds to dopamine transporters and regulates the effects of cocaine on dopamine neurotransmission and rodent self-administration behavior. [39] Elevating levels of synaptogyrin-3 made animals resilient to cocaine, and a possible future treatment for cocaine addiction might be based on targeting this protein. [39]

See also

Notes

  1. ↑ The study's authors stated that they wanted to know which effects and consequences of cocaine use would become visible with persons who are mainstream citizens or as close to that social stratum as possible

Related Research Articles

<span class="mw-page-title-main">Dextroamphetamine</span> CNS stimulant and isomer of amphetamine

Dextroamphetamine (INN:dexamfetamine) is a potent central nervous system (CNS) stimulant and enantiomer of amphetamine that is prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is also used as an athletic performance and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant. Dextroamphetamine is generally regarded as the prototypical stimulant.

<span class="mw-page-title-main">Opioid use disorder</span> Medical condition

Opioid use disorder (OUD) is a substance use disorder characterized by cravings for opioids, continued use despite physical and/or psychological deterioration, increased tolerance with use, and withdrawal symptoms after discontinuing opioids. Opioid withdrawal symptoms include nausea, muscle aches, diarrhea, trouble sleeping, agitation, and a low mood. Addiction and dependence are important components of opioid use disorder.

In internal medicine, relapse or recidivism is a recurrence of a past condition. For example, multiple sclerosis and malaria often exhibit peaks of activity and sometimes very long periods of dormancy, followed by relapse or recrudescence.

Substance dependence, also known as drug dependence, is a biopsychological situation whereby an individual's functionality is dependent on the necessitated re-consumption of a psychoactive substance because of an adaptive state that has developed within the individual from psychoactive substance consumption that results in the experience of withdrawal and that necessitates the re-consumption of the drug. A drug addiction, a distinct concept from substance dependence, is defined as compulsive, out-of-control drug use, despite negative consequences. An addictive drug is a drug which is both rewarding and reinforcing. ΔFosB, a gene transcription factor, is now known to be a critical component and common factor in the development of virtually all forms of behavioral and drug addictions, but not dependence.

<span class="mw-page-title-main">Caffeine dependence</span> Medical condition

Caffeine dependence is a condition characterized by a set of criteria, including tolerance, withdrawal symptoms, persistent desire or unsuccessful efforts to control use, and continued use despite knowledge of adverse consequences attributed to caffeine. It can appear in physical dependence or psychological dependence, or both. Caffeine is one of the most common additives in many consumer products, including pills and beverages such as caffeinated alcoholic beverages, energy drinks, pain reliever medications, and colas. Caffeine is found naturally in various plants such as coffee and tea. Studies have found that 89 percent of adults in the U.S. consume on average 200 mg of caffeine daily. One area of concern that has been presented is the relationship between pregnancy and caffeine consumption. Repeated caffeine doses of 100mg appeared to result in smaller size at birth in newborns. When looking at birth weight however, caffeine consumption did not appear to make an impact.

An addictive behavior is a behavior, or a stimulus related to a behavior, that is both rewarding and reinforcing, and is associated with the development of an addiction. There are two main forms of addiction: substance use disorders and behavioral addiction. The parallels and distinctions between behavioral addictions and other compulsive behavior disorders like bulimia nervosa and obsessive-compulsive disorder (OCD) are still being researched by behavioral scientists.

<span class="mw-page-title-main">Nicotine withdrawal</span> Process of withdrawing from nicotine addiction

Nicotine withdrawal is a group of symptoms that occur in the first few weeks after stopping or decreasing use of nicotine. Symptoms include intense cravings for nicotine, anger or irritability, anxiety, depression, impatience, trouble sleeping, restlessness, hunger, and difficulty concentrating. Withdrawal symptoms make it harder to quit nicotine products, and most methods for quitting smoking involve reducing nicotine withdrawal. Quit smoking programs can make it easier to quit. Nicotine withdrawal is recognized in both the American Psychiatric Association Diagnostic and Statistical Manual and the WHO International Classification of Diseases.

<span class="mw-page-title-main">Methamphetamine</span> Central nervous system stimulant

Methamphetamine is a potent central nervous system (CNS) stimulant that is mainly used as a recreational drug and less commonly as a second-line treatment for attention deficit hyperactivity disorder and obesity. Methamphetamine was discovered in 1893 and exists as two enantiomers: levo-methamphetamine and dextro-methamphetamine. Methamphetamine properly refers to a specific chemical substance, the racemic free base, which is an equal mixture of levomethamphetamine and dextromethamphetamine in their pure amine forms, but the hydrochloride salt, commonly called crystal meth, is widely used. Methamphetamine is rarely prescribed over concerns involving its potential for recreational use as an aphrodisiac and euphoriant, among other concerns, as well as the availability of safer substitute drugs with comparable treatment efficacy such as Adderall and Vyvanse. Dextromethamphetamine is a stronger CNS stimulant than levomethamphetamine.

Post-acute withdrawal syndrome (PAWS) is a hypothesized set of persistent impairments that occur after withdrawal from alcohol, opiates, benzodiazepines, antidepressants, and other substances. Infants born to mothers who used substances of dependence during pregnancy may also experience a PAWS. While PAWS has been frequently reported by those withdrawing from opiate and alcohol dependence, the research has limitations. Protracted benzodiazepine withdrawal has been observed to occur in some individuals prescribed benzodiazepines.

Psychological dependence is a cognitive disorder and a form of dependence that is characterized by emotional–motivational withdrawal symptoms upon cessation of prolonged drug use or certain repetitive behaviors. Consistent and frequent exposure to particular substances or behaviors is responsible for inducing psychological dependence, requiring ongoing engagement to prevent the onset of an unpleasant withdrawal syndrome driven by negative reinforcement. Neuronal counter-adaptation is believed to contribute to the generation of withdrawal symptoms through changes in neurotransmitter activity or altered receptor expression. Environmental enrichment and physical activity have been shown to attenuate withdrawal symptoms.

<span class="mw-page-title-main">Polysubstance dependence</span> A type of substance use disorder

Polysubstance dependence refers to a type of substance use disorder in which an individual uses at least three different classes of substances indiscriminately and does not have a favorite substance that qualifies for dependence on its own. Although any combination of three substances can be used, studies have shown that alcohol is commonly used with another substance. One study on polysubstance use categorized participants who used multiple substances according to their substance of preference. The results of a longitudinal study on substance use led the researchers to observe that excessively using or relying on one substance increased the probability of excessively using or relying on another substance.

<span class="mw-page-title-main">Benzodiazepine dependence</span> Medical condition

Benzodiazepine dependence defines a situation in which one has developed one or more of either tolerance, withdrawal symptoms, drug seeking behaviors, such as continued use despite harmful effects, and maladaptive pattern of substance use, according to the DSM-IV. In the case of benzodiazepine dependence, the continued use seems to be typically associated with the avoidance of unpleasant withdrawal reaction rather than with the pleasurable effects of the drug. Benzodiazepine dependence develops with long-term use, even at low therapeutic doses, often without the described drug seeking behavior and tolerance.

<span class="mw-page-title-main">Dopamine dysregulation syndrome</span> Medical condition

Dopamine dysregulation syndrome (DDS) is a dysfunction of the reward system observed in some individuals taking dopaminergic medications for an extended length of time. It typically occurs in people with Parkinson's disease (PD) who have taken dopamine agonist medications for an extended period of time. It is characterized by problems such as addiction to medication, gambling, or sexual behavior.

<span class="mw-page-title-main">Substance use disorder</span> Continual use of drugs (including alcohol) despite detrimental consequences

Substance use disorder (SUD) is the persistent use of drugs despite the substantial harm and adverse consequences to one's own self and others, as a result of their use. In perspective, the effects of the wrong use of substances that are capable of causing harm to the user or others, have been extensively described in different studies using a variety of terms such as substance use problems, problematic drugs or alcohol use, and substance use disorder.The National Institute of Mental Health (NIMH) states that "Substance use disorder (SUD) is a treatable mental disorder that affects a person's brain and behavior, leading to their inability to control their use of substances like legal or illegal drugs, alcohol, or medications. Symptoms can be moderate to severe, with addiction being the most severe form of SUD".Substance use disorders (SUD) are considered to be a serious mental illness that fluctuates with the age that symptoms first start appearing in an individual, the time during which it exists and the type of substance that is used. It is not uncommon for those who have SUD to also have other mental health disorders. Substance use disorders are characterized by an array of mental/emotional, physical, and behavioral problems such as chronic guilt; an inability to reduce or stop consuming the substance(s) despite repeated attempts; operating vehicles while intoxicated; and physiological withdrawal symptoms. Drug classes that are commonly involved in SUD include: alcohol (alcoholism); cannabis; opioids; stimulants such as nicotine (including tobacco), cocaine and amphetamines; benzodiazepines; barbiturates; and other substances.

<span class="mw-page-title-main">Amphetamine dependence</span> Medical condition

Amphetamine dependence refers to a state of psychological dependence on a drug in the amphetamine class. Stimulants such as amphetamines and cocaine do not cause somatic symptoms upon cessation of use but rather neurological-based mental symptoms.

<span class="mw-page-title-main">Addiction</span> Disorder resulting in compulsive behaviours

Addiction is a neuropsychological disorder characterized by a persistent and intense urge to use a drug or engage in a behavior that produces natural reward, despite substantial harm and other negative consequences. Repetitive drug use often alters brain function in ways that perpetuate craving, and weakens self-control. This phenomenon – drugs reshaping brain function – has led to an understanding of addiction as a brain disorder with a complex variety of psychosocial as well as neurobiological factors that are implicated in addiction's development.

<span class="mw-page-title-main">Cannabis use disorder</span> Continued use of cannabis despite clinically significant impairment

Cannabis use disorder (CUD), also known as cannabis addiction or marijuana addiction, is a psychiatric disorder defined in the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and ICD-10 as the continued use of cannabis despite clinically significant impairment.

About 1 in 7 Americans suffer from active addiction to a particular substance. Addiction can cause physical, psychological, and emotional harm to those who are affected by it. The American Society of Addiction Medicine defines addiction as "a treatable, chronic medical disease involving complex interactions among brain circuits, genetics, the environment, and an individual's life experiences. People with addiction use substances or engage in behaviors that become compulsive and often continue despite harmful consequences." In the world of psychology and medicine, there are two models that are commonly used in understanding the psychology behind addiction itself. One model is referred to as the disease model of addiction. The disease model suggests that addiction is a diagnosable disease similar to cancer or diabetes. This model attributes addiction to a chemical imbalance in an individual's brain that could be caused by genetics or environmental factors. The second model is the choice model of addiction, which holds that addiction is a result of voluntary actions rather than some dysfunction of the brain. Through this model, addiction is viewed as a choice and is studied through components of the brain such as reward, stress, and memory. Substance addictions relate to drugs, alcohol, and smoking. Process addictions relate to non-substance-related behaviors such as gambling, spending money, sexual activity, gaming, spending time on the internet, and eating.

Stimulant use disorder is a type of substance use disorder where the use of stimulants caused clinically significant impairment or distress. It is defined in the DSM-5 as "the continued use of amphetamine-type substances, cocaine, or other stimulants leading to clinically significant impairment or distress, from mild to severe". These psychoactive drugs, known as stimulants, are among the most widely used drugs in the world today, although not all stimulants can induce addiction. As of 1993, Approximately 200 million Americans have used some type of stimulant in the past year alone.

<span class="mw-page-title-main">Amorphinism</span> Medical condition

Amorphinism refers to the mental and physical symptoms arising when a morphine-addict is deprived of morphine. Morphine is a potent opioid agonist derived from poppy plants and was originally used as a painkiller before being abused for euphoric and relieving purposes. It gave rise to morphine dependence, which caused the development of morphine withdrawal symptoms when morphine is reduced or stopped.

References

  1. ↑ Pomara C, Cassano T, D'Errico S, Bello S, Romano AD, Riezzo I, Serviddio G (2012). "Data available on the extent of cocaine use and dependence: biochemistry, pharmacologic effects and global burden of disease of cocaine abusers". Current Medicinal Chemistry. 19 (33): 5647–57. doi:10.2174/092986712803988811. PMID   22856655.
  2. ↑ Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA: American Psychiatric Association Publishing. 2013. p. 561. ISBN   978-089042-555-8.
  3. ↑ "6C45 Disorders due to use of cocaine". ICD-11 - Mortality and Morbidity Statistics. Retrieved 20 November 2020.
  4. 1 2 Cocaine Use and Its Effects
  5. ↑ Walsh, Karen (October 2010). "Teen Cocaine Use". Inspirations for Youth and Family. Archived from the original on 13 February 2018. Retrieved 12 December 2013.
  6. 1 2 LeVert, Suzanne (2006). Drugs: The Facts About Cocaine. New York: Marshall Cavendish Benchmark. pp. 41, 76.
  7. ↑ Gawin, F.H. (1991). "Cocaine addiction: Psychology and neurophysiology". Science . 251 (5001): 1580–6. Bibcode:1991Sci...251.1580G. doi:10.1126/science.2011738. PMID   2011738. S2CID   26660048.
  8. 1 2 3 Abuse, National Institute on Drug. "What is Cocaine?". National Institute on Drug Abuse. Retrieved 9 May 2021.
  9. 1 2 3 4 "Department of Health | The cocaine withdrawal syndrome". www1.health.gov.au. Archived from the original on 3 December 2020. Retrieved 10 May 2021.
  10. 1 2 "National Survey on Drug Use and Health". nsduhweb.rti.org. Retrieved 9 May 2021.
  11. ↑ Abuse, National Institute on Drug. "Cocaine". National Institute on Drug Abuse. Retrieved 1 May 2021.
  12. ↑ Tierney, John (16 September 2013). "The Rational Choices of Crack Addicts". New York Times. Retrieved 16 September 2013.
  13. ↑ Wagner, FA (2002), "From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol", Neuropsychopharmacology, 26 (4): 479–88, doi: 10.1016/S0893-133X(01)00367-0 , PMID   11927172
  14. ↑ O'Brien MS, Anthony JC (2005). "Risk of becoming cocaine dependent: epidemiological estimates for the United States, 2000–2001". Neuropsychopharmacology. 30 (5): 1006–1018. doi: 10.1038/sj.npp.1300681 . PMID   15785780.
  15. ↑ Cohen, Peter; Sas, Arjan (1994). "Cocaine use in Amsterdam in non deviant subcultures". Addiction Research. 2 (1): 71–94. doi:10.3109/16066359409005547.
  16. ↑ "Cocaine and Addiction". Niznik Behaviour Health.
  17. ↑ Palinkas, L. A. (17 January 2008). "Cognitive behavioural therapy reduced cocaine abuse compared with 12 step facilitation". Evidence-Based Mental Health. 2 (2). ebmh.bmj.com: 51. doi: 10.1136/ebmh.2.2.51 . S2CID   146360156 . Retrieved 25 August 2012.
  18. 1 2 Barbee, Britton R.; Gourley, Shannon L. (1 June 2022). "Brain systems in cocaine abstinence-induced anxiety-like behavior in rodents: A review". Addiction Neuroscience. 2: 100012. doi: 10.1016/j.addicn.2022.100012 . ISSN   2772-3925. PMC   10361393 . PMID   37485439. S2CID   247587106.
  19. ↑ Gawin, Frank H. (1 February 1986). "Abstinence Symptomatology and Psychiatric Diagnosis in Cocaine Abusers: Clinical Observations". Archives of General Psychiatry. 43 (2): 107–113. doi:10.1001/archpsyc.1986.01800020013003. ISSN   0003-990X. PMID   3947206.
  20. ↑ McHugh, R. Kathryn; Hearon, Bridget A.; Otto, Michael W. (September 2010). "Cognitive-Behavioral Therapy for Substance Use Disorders". Psychiatric Clinics of North America. 33 (3): 511–525. doi:10.1016/j.psc.2010.04.012. PMC   2897895 . PMID   20599130.
  21. ↑ Carroll, Kathleen M.; Kiluk, Brian D.; Nich, Charla; DeVito, Elise E.; Decker, Suzanne; LaPaglia, Donna; Duffey, Dianne; Babuscio, Theresa A.; Ball, Samuel A. (1 April 2014). "Toward empirical identification of a clinically meaningful indicator of treatment outcome: Features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes". Drug and Alcohol Dependence. 137: 3–19. doi:10.1016/j.drugalcdep.2014.01.012. ISSN   0376-8716. PMC   4042667 . PMID   24556275.
  22. ↑ Margolin, Arthur; et al. (2 January 2002). "Acupuncture for the treatment of cocaine addiction: A randomized controlled trial". The Journal of the American Medical Association. 287 (1): 55–63. doi: 10.1001/jama.287.1.55 . PMID   11754709.
  23. ↑ Otto, Katharine C.; Quinn, Colin; Sung, Yung-Fong (Spring 1998). "Auricular acupuncture as an adjunctive treatment for cocaine addiction: A pilot study". The American Journal on Addictions. 7 (2): 164–170. doi:10.1111/j.1521-0391.1998.tb00331.x. PMID   9598220.
  24. ↑ Page, R.A.; Handleya, G.W. (1993). "The use of hypnosis in cocaine addiction". American Journal of Clinical Hypnosis. 36 (2): 120–123. doi:10.1080/00029157.1993.10403054. PMID   8259763.
  25. ↑ Potter, Greg (2004). "Intensive therapy: Utilizing hypnosis in the treatment of substance abuse disorders". American Journal of Clinical Hypnosis. 47 (1): 21–28. doi:10.1080/00029157.2004.10401472. PMID   15376606. S2CID   42943267.
  26. 1 2 Minozzi, S; Cinquini, M; Amato, L; Davoli, M; Farrell, MF; Pani, PP; Vecchi, S (April 2015). "Anticonvulsants for cocaine dependence". Cochrane Database of Systematic Reviews (Systematic Review & Meta-Analysis). 17 (4): CD006754. doi:10.1002/14651858.CD006754.pub4. PMC   8812341 . PMID   25882271.
  27. ↑ Singh, M; Keer, D; Klimas, J; Wood, E; Werb, D (August 2016). "Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials". Addiction (Systematic Review & Meta-Analysis). 111 (8): 1337–46. doi:10.1111/add.13328. hdl: 10147/596595 . PMID   26826006. S2CID   34637139.
  28. ↑ Indave, BI; Minozzi, S; Pani, PP; Amato, L (March 2016). "Antipsychotic medications for cocaine dependence". Cochrane Database of Systematic Reviews (Systematic Review and Meta-Analysis). 3 (6): CD006306. doi:10.1002/14651858.CD006306.pub3. PMC   8750745 . PMID   26992929.
  29. ↑ Mariani, JJ; Levin, FR (June 2012). "Psychostimulant treatment of cocaine dependence". Psychiatric Clinics of North America (Review). 35 (2): 425–39. doi:10.1016/j.psc.2012.03.012. PMC   3417072 . PMID   22640764.
  30. ↑ Danish, Muhammad (5 December 2016). "Ibogaine treatment Clinic". Avante Institute. Retrieved 7 May 2021.
  31. ↑ Group, Clear Sky (1 August 2018). "Is Ibogaine Illegal in the United States?". Clear Sky Recovery. Retrieved 6 May 2021.
  32. ↑ Karila L; Gorelick D; Weinstein A; et al. (May 2008). "New treatments for cocaine dependence: a focused review". Int. J. Neuropsychopharmacol. 11 (3): 425–38. doi: 10.1017/S1461145707008097 . PMID   17927843.
  33. ↑ Cherstniakova SA, Bi D, Fuller DR, Mojsiak JZ, Collins JM, Cantilena LR (September 2001). "Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes". Drug Metab. Dispos. 29 (9): 1216–20. PMID   11502731.
  34. ↑ "Chemistry, Design, and Structure-Activity Relationship of Cocaine Antagonists". Satendra Singh et al. Chem. Rev. 2000, 100. 925-1024. PubMed; Chemical Reviews (Impact Factor: 45.66). 04/2000; 100(3):925-1024 American Chemical Society; 2000, ISSN   0009-2665 ChemInform; May, 16th 2000, Volume 31, Issue 20, DOI: 10.1002/chin.200020238. Mirror hotlink.
  35. ↑ Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR (July 2005). "Vaccine pharmacotherapy for the treatment of cocaine dependence". Biol. Psychiatry. 58 (2): 158–64. doi:10.1016/j.biopsych.2005.04.032. PMID   16038686. S2CID   22415520.
  36. ↑ Wadman, Meredith (29 August 2017). "Brain-altering magnetic pulses could zap cocaine addiction". Science Magazine . American Association for the Advancement of Science . Retrieved 1 September 2017.
  37. ↑ Rachid, Fady (1 January 2018). "Neurostimulation techniques in the treatment of cocaine dependence: A review of the literature". Addictive Behaviors. 76: 145–155. doi:10.1016/j.addbeh.2017.08.004. ISSN   0306-4603. PMID   28822321.
  38. 1 2 Siciliano, Cody A.; Saha, Kaustuv; Calipari, Erin S.; Fordahl, Steve C.; Chen, Rong; Khoshbouei, Habibeh; Jones, Sara R. (10 January 2018). "Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation". The Journal of Neuroscience. 38 (2): 484–497. doi:10.1523/JNEUROSCI.2604-17.2017. ISSN   1529-2401. PMC   5761621 . PMID   29175958.
  39. 1 2 Peck, Emily Grace; Holleran, Katherine M.; Curry, Alyson M.; Holter, Kimberly Marie; Estave, Paige; Sens, Jonathon P; Locke, Jason; Ortelli, Olivia; George, Brianna (29 July 2024), Synaptogyrin-3 Prevents Cocaine Addiction and Dopamine Deficits, doi:10.1101/2024.07.27.605436 , retrieved 9 August 2024

Reference notes

  1. ↑ [34] ←Page #928 (4th page of article) ¶4. §(1), (2) & (3); Lines 10—12 & 15—18 of aforementioned 4th ¶.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.